Literature DB >> 29536138

Reliability and validity of the Tigrigna version of the Pelvic Floor Distress Inventory-Short Form 20 (PFDI-20) and Pelvic Floor Impact Questionnaire-7 (PFIQ-7).

Gelila K Goba1, Awol Yeman Legesse2, Yibrah Berhe Zelelow2, Mussie Alemayehu Gebreselassie3, Rebecca G Rogers4, Kimberly S Kenton5, Margaret G Mueller5.   

Abstract

INTRODUCTION AND HYPOTHESIS: This study adapted the Pelvic Floor Distress Inventory-Short Form 20 (PFDI-20) and the Pelvic Floor Impact Questionnaire-7 (PFIQ-7) into the Tigrigna language of northern Ethiopia and validated the their reliability and validity through patient interviews.
METHODS: Expert translation, cognitive interviewing, and patient interviews using translated questionnaires were conducted. A subset of women was reinterviewed 1 week later. Intraclass correlation coefficients (ICC), Bland-Altman analysis, and Cronbach's alpha values were assessed. Total and subscale scores were compared between women with and without pelvic floor disorders (PFDs) using the Mann-Whitney U test. Spearman's correlation coefficients were used to compare severity of pelvic organ prolapse (POP) stage according to the POP Quantification (POP-Q) system and PFDI-20 and PFIQ-7 and subscale scores.
RESULTS: Ten women participated in cognitive interviewing and 118 age 49 ± 10 years, mean ± standard deviation (SD) with and without PFDs were interviewed using the translated questionnaires, both of which presented adequate face validity and test-retest reliability [intraclass correlation coefficient (ICC) 0.765-0.969, p < 0.001]. Construct validity was significant between clinical symptoms and full forms (p <0.001) and their subscales (p <0.001), except for the Pelvic Organ Prolapse Impact Questionnaire (POPIQ). Differences between first and second scores on total PFDI-20 and PFIQ-7 and subscales largely fell within 0 ± 1.96 SD. Cronbach's alpha values were 0.891-0.930 for PFDI-20 and 0.909-0.956 for PFIQ-7 (p < 0.001). Analysis of known groups showed differences PFDI-20 and PFIQ-7 scores between women with and without PFDs (p <0.001 for full forms and subscales, except for anal incontinence (AI) and the Urinary Impact Questionnaire (UIQ)/POPIQ.
CONCLUSION: The translated Tigrigna versions of the PFDI-20 and PFIQ-7 questionnaires are reliable, valid, and feasible tools to evaluate symptoms and quality of life (QoL) of Tigrigna-speaking Ethiopian women with PFDs.

Entities:  

Keywords:  Ethiopia; PFDI-20; PFIQ-7; Pelvic floor disorder

Mesh:

Year:  2018        PMID: 29536138     DOI: 10.1007/s00192-018-3583-9

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  4 in total

1.  Development and initial validation of a pictorial survey to assess for symptomatic pelvic organ prolapse and urinary incontinence in western Kenya.

Authors:  Michele O'Shea; Jackton Omoto; Megan Huchko; Stephen Gwer
Journal:  Int Urogynecol J       Date:  2022-06-30       Impact factor: 1.932

Review 2.  Questionnaires to evaluate pelvic floor dysfunction in the postpartum period: a systematic review.

Authors:  Lea Tami Suzuki Zuchelo; Italla Maria Pinheiro Bezerra; Adna Thaysa Marcial Da Silva; Jéssica Menezes Gomes; José Maria Soares Júnior; Edmund Chada Baracat; Luiz Carlos de Abreu; Isabel Cristina Esposito Sorpreso
Journal:  Int J Womens Health       Date:  2018-08-08

3.  Postural Sensorimotor Control on Anorectal Pressures and Pelvic Floor Muscle Tone and Strength: Effects of a Single 5P® LOGSURF Session. A Cross-Sectional Preliminary Study.

Authors:  Laura Fuentes-Aparicio; Beatriz Arranz-Martín; Beatriz Navarro-Brazález; Javier Bailón-Cerezo; Beatriz Sánchez-Sánchez; María Torres-Lacomba
Journal:  Int J Environ Res Public Health       Date:  2021-04-02       Impact factor: 3.390

4.  Role of Preoperative and Postoperative Pelvic Floor Distress Inventory-20 in Evaluation of Posthysterectomy Vault Prolapse.

Authors:  Jai Bhagwan Sharma; Mukesh Kumar; K K Roy; Rajesh Kumari; Kavita Pandey
Journal:  J Midlife Health       Date:  2021-07-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.